Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
ikegami Toru Last modified date:2019.08.08

Lecturer / Graduate school of medical science / Liver Surgery / Kyushu University Hospital


Papers
1. Ikegami T, Yoshizumi T, Soejima Y, Mori M., Effective and Safe Living Donor Hepatectomy Under Intermittent Inflow Occlusion and Outflow Pressure Control., J Gastrointest Surg, 10.1007/s11605-019-04196-y., 2018.10, One hundred and fifty-six cases of right lobe LDH was performed, infrahepatic vena cava clamping was applied for 74 cases (47.4%) and Pringle maneuver was for 108 cases (69.2%). The mean vascular occlusion time was 31 ± 13 min for vena cava clamping, and 32 ± 16 min for Pringle’s maneuver, respectively. The mean operative time and blood loss was 275 ± 45 min and 214 ± 101 ml, respectively. The mean peak total bilirubin and aspartate aminotransferase was 1.8 ± 0.8 mg/dl and 417 ±158 IU/L, respectively. Grade III post-operative complications was observed in three cases (1.8%) including intra-abdominal bleeding (n=1), portal vein thrombosis (n=1) and biliary leakage (n=1), successfully treated. Thus, our smaller amount of operative blood loss (214 ml vs. 500 ml) might be associated with decreased grade III complication rate (1.3% vs. 16.7%), compared with the results by Sultan, et al (1)..
2. Ikegami T, Yoshizumi T, Ohira M, Harada N, Soejima Y, Maehara Y., Indication of living donor liver transplantation for septuagenarians from double equipoise theory. , Am J Transplant. , 18, 278-279, 2018.05.
3. 11. Ikegami T, Yoshizumi T, Uchiyama H, Soejima Y, Harada N, Maehara Y., Hepatic artery reconstruction in living donor liver transplantation using surgical loupes: Achieving low rate of hepatic arterial thrombosis in 741 consecutive recipients-tips and tricks to overcome the poor hepatic arterial flow., Liver Transpl. , 23, 1081-1082, 2017.11.
4. ikegami Toru, Left lobe living donor liver transplantation in adults: What is the safety limit?, 10.1002/lt.24611, 2017.06, Small-for-size syndrome (SFSS) is the most significant cause of graft loss after living donor liver transplantation (LDLT), especially after left lobe (LL) LDLT in adults. The safety limit of applying LL-LDLT in adults without severe SFSS with a high rate of lethality needs to be determined. A total of 207 LL-LDLTs in adults since September 2005 were evaluated to analyze the risk factors for severe SFSS, defined as a serum total bilirubin concentration of ≥20.0 mg/dL after LDLT. Although there were no significant differences in cumulative graft survival after LDLT between medium grafts (graft volume [GV] to standard liver volume [SLV] ratio ≥ 40.0%), small grafts (35.0% ≤ GV/SLV < 40.0%), and extra small grafts (GV/SLV < 35.0%), patients with severe SFSS showed a significantly lower 5-year graft survival rate than those without (42.9% versus 94.3%, respectively; P < 0.001). Multivariate analysis for severe SFSS after LL-LDLT showed that donor age of ≥48 years (P = 0.01), Model for End-Stage Liver Disease (MELD) score of ≥ 19 (P < 0.01), and end portal venous pressure of ≥19 mm Hg (P = 0.04) were the significant and independent factors for severe SFSS after LL-LDLT. Within such high-risk subgroups of patients with a donor age of ≥48 years or MELD score of ≥ 19 before LDLT, operative blood loss volume of ≥8.0 L was a risk factor for severe SFSS. LL-LDLT in adults could be indicated and provide acceptable outcomes for the combinations of donors aged < 48 years and recipients with a MELD score of <19. Smaller grafts might yield acceptable outcomes in appropriately selected donor-recipient combinations. .
5. ikegami Toru,
Eversion Technique to Prevent Biliary Stricture After Living Donor Liver Transplantation in the Universal Minimal Hilar Dissection Era.
, 10.1097/TP.0000000000001533, 2017.06, Abstract
BACKGROUND:
Biliary anastomosis stricture (BAS) is still among the major concerns after living donor liver transplantation (LDLT), even after the technical refinements including the universal use of the blood flow-preserving hilar dissection technique. The aim of this study is to investigate what are still the factors for BAS after LDLT.
METHODS:
An analysis of 279 adult-to-adult LDLT grafts (left lobe, n = 161; right lobe, n = 118) with duct-to-duct biliary reconstruction, since the universal application of minimal hilar dissection technique and gradual introduction of eversion technique, was performed.
RESULTS:
There were 39 patients with BAS. Univariate analysis showed that a right lobe graft (P = 0.008), multiple bile ducts (P < 0.001), ductoplasty (P < 0.001), not using the eversion technique (P = 0.004) and fewer biliary stents than bile duct orifices (P = 0.002) were among the factors associated with BAS. The 1-year and 5-year BAS survival rates were 17.7% and 21.2% in the noneversion group (n = 134), and 6.2% and 7.9% in the eversion group (n = 145), respectively (P = 0.002). The perioperative factors including graft biliary anatomy were not different between everted (n = 134) and noneverted (n = 145) patients.
CONCLUSIONS:
The application of eversion technique under minimal hilar dissection technique could be a key for preventing BAS in duct-to-duct biliary reconstruction in LDLT..
6. ikegami Toru, The learning curves in living donor hemiliver graft procurement using small upper midline incision., Clin Transplant., 10.1111/ctr.12850, 2016.12, The learning curve for performing living donor hemiliver procurement (LDHP) via small upper midline incision (UMI) has not been determined. Living donors (n=101) who underwent LDHP via UMI were included to investigate the learning curve using cumulative sum analysis. The cumulative sum analysis showed that nine cases for right lobe (case #23) and 19 cases for left lobe (case #32 in the whole series) are needed for stable and acceptable surgical outcomes in LDHP via UMI. The established phase (n=69, since case #33) had a significantly shorter operative time, a smaller incision size, and less blood loss than the previous learning phase (n=32, serial case number up to the last 19th left lobe case). Multivariate analysis showed that the learning phase, high body mass index ≥25 kg/m2 , and left lobe graft procurement are the factors associated with surgical events including operative blood loss ≥400 mL, operative time ≥300 minutes, or surgical complications ≥Clavien-Dindo grade II. There is an obvious learning curve in performing LDHP via UMI, and 32 cases including both 19 cases for left lobe and nine cases for right lobe are needed for having stable and acceptable surgical outcomes..
7. ikegami Toru, Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma., Anticancer Res., 10.21873/anticanres.11395, 2017.06, Abstract
BACKGROUND:
Treatment strategies for lymph node (LN) metastasis after liver transplantation (LT) for hepatocellular carcinoma (HCC) have not been studied.
PATIENTS AND METHODS:
The treatment modes and outcomes in patients with LN metastasis after LT (n=6) for HCC were reviewed.
RESULTS:
The mean time from LT to LN recurrence was 2.0±1.3 years, and the locations of the LNs recurrences included the phrenic (n=2), common hepatic artery (n=2), inferior vena cava (n=1) and gastric (n=1) regions. Treatments included surgery alone (n=3), surgery followed by chemoradiation (n=1), radiation followed by chemotherapy (n=1), and chemotherapy, radiation and sorafenib (n=1). Although the patients receiving non-surgical treatments (n=3) died within 1.2 years, those who underwent surgical removal of the metastatic LNs survived 11.2 years, 4.5 years and 0.8 years, respectively, without any signs of re-recurrence.
CONCLUSION:
Surgical resection is the only feasible and potentially curative treatment for LN metastasis after LT for HCC..
8. ikegami Toru, Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience., Transplant Proc., 10.1016/j.transproceed., 47, 3, 730-732, 2016.04.
9. ikegami Toru, Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation., Hepatol Res., 10.1111/hepr.12546., 46, 3, E136-E45, 2016.03.
10. ikegami Toru, D-MELD as a predictor of early graft mortality in adult-to-adult living-donor liver transplantation., Transplantation. 2014 Feb 27;97(4):457-62. doi: 10.1097/01.TP.0000435696.23525.d0., 2014.02, Ensuring a good match between donor and recipient is critically important to achieve acceptable graft outcomes after living-donor liver transplantation (LDLT). Our objective was to evaluate the product of donor age and Model for End-stage Liver Disease score (D-MELD) as a predictor of graft survival after LDLT.
METHODS:
We retrospectively evaluated the records of 355 adults who underwent LDLT for chronic liver disease and explored the relationship between D-MELD and graft outcome.
RESULTS:
High MELD score and advanced donor age were significantly associated with graft survival; D-MELD had the strongest association with in-hospital mortality. Receiver operating characteristic curve analysis showed that a D-MELD score of 462 had the highest sensitivity for predicting in-hospital mortality. Patients were allocated to three groups based on D-MELD (Class A [≤449; n=142], Class B [450-899; n=163], and Class C [≥900; n=50]) and were found to have stratified cumulative 2-year graft survivals of 94.1%, 85.3%, and 63.1%, respectively (P<0.01). Although D-MELD Class C patients had larger graft volume-to-standard liver volume ratio (P<0.01) and received right lobe grafts more often (P<0.01), they still exhibited significantly higher rates of primary graft dysfunction (P<0.01) and in-hospital mortality (P<0.01). Outcomes in D-MELD Class C were significantly worse in hepatitis C-positive patients (P<0.05).
CONCLUSIONS:
The D-MELD score is a simple and reliable predictor of early graft survival that assists the matching of donors and recipients in LDLT in adults..
11. ikegami Toru, Small upper midline incision for living donor hemi-liver graft procurement in adults., J Am Coll Surg. 2014 Sep;219(3):e39-43. doi: 10.1016/j.jamcollsurg.2014.04.021. Epub 2014 Jun 21., 2014.09.
12. ikegami Toru, Pathological analysis of opened round ligaments as venous patch grafts in living donor liver transplantation., Liver Transpl.
13. ikegami Toru, Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living donor liver transplantation., Transplantation.
14. ikegami Toru, Strategies for successful left-lobe living donor liver transplantation in the 250 consecutive adult cases in a single center., J Am Coll Surg, .
15. 池上 徹, 3D printing of the liver in living donor liver transplantation, Nat Rev Gastroenterol Hepatol,, 2013.10.
16. 池上 徹, 吉住 朋晴, Bacterial Sepsis after Living Donor Liver Transplantation: The Impact of Early Enteral Nutrition, Journal fo the American collage of surgeons, 2012.10, Background: Bacterial sepsis is a significant problem that must be addressed after living donor liver transplantation (LDLT).
Study Design: A retrospective analysis of 346 adult-to-adult LDLT patients was performed.
Results: Forty-six patients (13.3%) experienced bacterial sepsis, with primary and secondary origins in 23.9% and 76.1%, respectively. Gram-negative bacteria accounted for 71.7% of the bacteria isolated. The 2-year cumulative graft survival rate in patients with bacterial sepsis was 45.7%. Patients with bacterial sepsis secondary to pneumonia (n=12) had poorer 2-year graft survival rate (16.7%) than did those with primary or other types of secondary sepsis (p=0.004). Multivariate analysis showed that intraoperative massive blood loss >10L (p<0.001) and no enteral feeding started within 48 hours after transplantation (p=0.005) were the significant risk factors for bacterial sepsis. Among patients who received enteral nutrition, the incidence of bacterial sepsis in patients who received enteral nutrition within 48 hours (n=135) or later than 48 hours (n=57) was 5.9% and 21.0%, respectively (p=0.002). The incidence of early graft loss was 8-fold higher in recipients with massive intraoperative blood loss without early enteral nutrition (p<0.001).
Conclusions: Early enteral nutrition was associated with significantly reduced risk of developing bacterial sepsis after LDLT..
17. Ikegami T, Maeda T, Kayashima H, Oki E, Yoshizumi T, Sakaguchi Y, Toh Y, Shirabe K, Maehara Y., Soft coagulation, polyglycolic acid felt and fibrin glue for preventing pancreatic fistula after distal pancreatectomy., Surg Today, in press, 2011.05.
18. Yoshizumi T, Shirabe K, Soejima Y, Taketomi A, Ikegami T, Uchiyama H, Harada N, Ijichi H, Maehara Y., Living donor liver transplantation in patients who have received pretransplant treatment for hepatocellular carcinoma., Transplantation., 91, 8, e61-62, 2011.04.
19. Ikegami T, Maeda T, Oki E, Kayashima H, Ohgaki K, Sakaguchi Y, Shirabe K, Maehara Y. , Antegrade en bloc Distal Pancreatectomy with Plexus Hanging Maneuver, J Gastrointest Surg, 15, 4, 690-693, 2011.04.
20. Ikegami T, Shirabe K, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Maehara Y., The impact of renal replacement therapy before or after living donor liver transplantation, Clin Transpl, Epub ahead of print, 2011.03.
21. Kawate H, Taketomi A, Watanabe T, Nomura M, Kato M, Sakamoto R, Ikegami T, Soejima Y, Maehara Y, Takayanagi R., Hypophosphatemic osteomalacia as a long-term complication after liver transplantation. , Transplantation, 91, 1, e6-8, 2011.01.
22. Hashimoto K, Nishizaki T, Yoshizumi T, Uchiyama H, Okano S, Ikegami T, Yanaga K, Sugimachi K. , Beneficial effect of FR167653 on cold ischemia-reperfusion injury in rat liver transplantation. , Transplantation, 70, 9, 1318-1322, 2010.10.
23. Hashimoto K, Nishizaki T, Yoshizumi T, Uchiyama H, Okano S, Ikegami T, Yanaga K, Sugimachi K. , Beneficial effect of FR167653 on cold ischemia-reperfusion injury in rat liver transplantation. , Transplantation, 70, 9, 1318-1322, 2010.10.
24. Hashimoto K, Nishizaki T, Yoshizumi T, Uchiyama H, Okano S, Ikegami T, Yanaga K, Sugimachi K. , Beneficial effect of FR167653 on cold ischemia-reperfusion injury in rat liver transplantation. , Transplantation, 70, 9, 1318-1322, 2010.10.
25. Taketomi A, Toshima T, Kitagawa D, Motomura T, Takeishi K, Mano Y, Kayashima H, Sugimachi K, Aishima S, Yamashita Y, Ikegami T, Gion T, Uchiyama H, Soejima Y, Maeda T, Shirabe K, Maehara Y. , Predictors of Extrahepatic Recurrence After Curative Hepatectomy for Hepatocellular Carcinoma., Ann Surg Oncol, 17, 10, 2740-2746, 2010.10.
26. Uchiyama H, Shirabe K, Taketomi A, Soejima Y, Ninomiya M, Kayashima H, Ikegami T, Maehara Y. , Extra-anatomical hepatic artery reconstruction in living donor liver transplantation: can this procedure save hepatic grafts?, Liver Transpl, 16, 9, 1054-1061, 2010.09.
27. Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Soejima Y, Shirabe K, Maehara Y., Improved Results of a Surgical Resection for the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation., Ann Surg Oncol, 17, 9, 2283-2289, 2010.09.
28. Yoshizumi T, Shirabe K, Soejima Y, Taketomi A, Yamashita N, Ikegami T, Uchiyama H, Kayashima H, Ninomiya M, Maehara Y., Living Donor Liver Transplantation in Patients Older Than 60 Years., Transplantation, 90, 4, 433-437, 2010.08.
29. Soejima Y, Takeishi K, Ikegami T, Uchiyama H, Taketomi A, Maehara Y., All-in-one ex vivo self-reconstruction technique using an autologous inferior vena cava for a right lobe liver graft with multiple and complex venous orifices., Liver Transpl, 90, 4, 433-437, 2010.07.
30. Uchiyama H, Harada N, Sanefuji K, Kayashima H, Taketomi A, Soejima Y, Ikegami T, Shimada M, Maehara Y., Dual hepatic artery reconstruction in living donor liver transplantation using a left hepatic graft with 2 hepatic arterial stumps., Surgery, 147, 6, 878-886, 2010.06.
31. Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y., Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation., J Hepatol, 52, 5, 672-680, 2010.05.
32. Fukuhara T, Ikegami T, Morita K, Umeda K, Ueda S, Nagata S, Sugimachi K, Gion T, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y., Impact of preoperative serum sodium concentration in living donor liver transplantation., J Gastroenterol Hepatol, 25, 5, 978-984, 2010.05.
33. Uchiyama H, Ikegami T, Soejima Y, Ninomiya M, Kayashima H, Taketomi A, Shirabe K, Maehara Y., Use of recipient's left hepatic artery for artery reconstruction in right lobe living donor liver transplantation with duct-to-duct anastomosis., Transplantation, 89, 8, 1016-1021, 2010.04.
34. Sanefuji K, Iguchi T, Ueda S, Nagata S, Sugimachi K, Ikegami T, Gion T, Soejima Y, Taketomi A, Maehara Y., New prediction factors of small-for-size syndrome in living donor adult liver transplantation for chronic liver disease., Transpl Int, 23, 4, 350-357, 2010.04.
35. Fukuhara T, Takeishi K, Toshima T, Morita K, Ueda S, Iguchi T, Nagata S, Sugimachi K, Ikegami T, Gion T, Soejima Y, Taketomi A, Maehara Y., Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis., Hepatol Res, 40, 2, 171-178, 2010.02.
36. Sanefuji K, Taketomi A, Iguchi T, Sugimachi K, Ikegami T, Yamashita Y, Gion T, Soejima Y, Shirabe K, Maehara Y. , Significance of DNA Polymerase Delta Catalytic Subunit p125 Induced by Mutant p53 in the Invasive Potential of Human Hepatocellular Carcinoma., Oncology, 79, 3-4, 229-237, 2010.01.
37. Ikegami T, Soejima Y, Shirabe K, Taketomi A, Yoshizumi T, Uchiyama H, Fukuhara T, Ikeda T, Maehara Y., Evolving Strategies to Prevent Biliary Strictures after Living Donor Liver Transplantation, Transplant Proc, 42, 9, 3624-3629, 2010.01.
38. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Harada N, Iguchi T, Hashimoto N, Maehara Y., Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation., Transplantation, 88, 3, 303-307, 2009.08.
39. Shoji F, Kawano D, Ikegami T, Soejima Y, Taketomi A, Yano T, Maehara Y., Surgical resection of pulmonary malignant tumors after living donor liver transplantation., Ann Thorac Surg, 88, 1, 206-211, 2009.07.
40. Ikegami T, Shimada M, Imura S, Soejima Y, Yoshizumi T, Hanaoka J, Morine Y, Maehara Y. , The changes of the medial right lobe, transplanted with left lobe liver graft from living donors., Transplantation, 87, 5, 698-703, 2009.03.
41. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. , The impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living door liver transplantation., Transplantation, 87, 4, 531-537, 2009.02.
42. Taketomi A, Kayashima H, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Yamashita Y, Harada N, Shimada M, Maehara Y. , Donor risk in adult-to-adult living donor liver transplantation: Impact of left lobe graft., Transplantation, 87, 3, 445-450, 2009.02.
43. Ikegami T, Soejima Y, Taketomi A, Kawanaka H, Yoshizumi T, Shimada M, Maehara Y. , Persistent hypersplenism after living donor liver transplantation., Hepatogastroenterology, 56, 91-92, 778-782, 2009.01.
44. Uehara H, Kawanaka H, Akahoshi T, Tomikawa M, Kinjo N, Hashimoto N, Ikegami T, Soejima Y, Taketomi A, Maehara Y., The feasibility and effectiveness of a hand-assisted laparoscopic splenectomy for hypersplenism in patients after living-donor liver transplantation., Surg Laparosc Endosc Percutan Tech, 19, 6, 484-187, 2009.01.
45. Kanamoto M, Shimada M, Ikegami T, Imura S, Morine Y, Kanemura H, Arakawa Y, Nii A. , Real-Time Elastography for noninvasive diagnosis of hepatic fibrosis., J Hepatobiliary Pancreat Surg, 16, 4, 463-467, 2009.01.
46. Morine Y, Imura S, Kanemura H, Ikemoto T, Yoshizumi T, Ikegami T, Shimada M. , Usefullness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for advanced biliary tract carcinoma. , Hepatogastroenterology, 56, 90, 307-312, 2009.01.
47. Hanaoka J, Shimada M, Uchiyama H, Ikegami T, Imura S, Morine Y, Kanemura H., A simple formula to calculate the liver drainage volume of the accessory right hepatic vein using its diameter alone., Surgery, 146, 2, 264-268, 2009.01.
48. Arakawa Y, Shimada M, Uchiyama H, Ikegami T, Yoshizumi T, Imura S, Morine Y, Kanemura H., Beneficial effects of splenectomy on massive hepatectomy model in rats., Hepatol Res, 39, 4, 391-397, 2009.01.
49. Nii A, Shimada M, Ikegami T, Harino Y, Imura S, Morine Y, Kanemura H, Arakawa Y, Sugimoto K., Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma., Hepatol Res, 39, 3, 274-281, 2009.01.
50. Morine Y, Shimada M, Torii M, Imura S, Ikegami T, Kanemura H, Arakawa Y, Hanaoka J, Kanamoto M, Nii A, Yamazaki N., Optimal Administration of Tacrolimus in Reduced-Size Liver, Dig Dis Sci, 54, 8, 1789-1793, 2009.01.
51. Fukuhara T, Umeda K, Toshima T, Takeishi K, Morita K, Nagata S, Sugimachi K, Ikegami T, Gion T, Soejima Y, Taketomi A, Maehara Y. , Congestion of the donor remnant right liver after left lobe donation., Transplant Int, 22, 8, 837-844, 2009.01.
52. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Fukuhara T, Kotoh K, Shimoda S, Kato M, Maehara Y. , The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C., Transplant Proc, 41, 10, 4246-4252, 2009.01.
53. Ikegami T, Toshima T, Takeishi K, Soejima Y, Kawanaka H, Yoshizumi T, Taketomi A, Maehara Y., Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension., J Am Coll Surg, 208, 2, e1-4, 2009.01.
54. Ikegami T, Taketomi A, Ohta R, Soejima Y, Yoshizumi T, Harada N, Shimada M, Maehara Y. , The risks of HBV infection after liver transplantation from HBc antibody positive donor to HBs antibody positive recipient. , Hepatogastroenterology, 55, 88, 2162-2165, 2008.10.
55. Soejima Y, Fukuhara T, Morita K, Yoshizumi T, Ikegami T, Yamashita Y, Sugimachi K, Taketomi A, Maehara Y., A simple hilar dissection technique preserving maximum blood supply to the bile duct in living donor liver transplantation. , Transplantation, 86, 10, 1468-1469, 2008.10.
56. Tokunaga T, Ikegami T, Yoshizumi T, Imura S, Morine Y, Shinohara H, Shimada M. , Beneficial Effects of Fluvastatin on Massive Hepatectomy in Rats., Dig Dis Sci, 53, 11, 2989-2994, 2008.10.
57. Harino Y, Imura S, Kanemura H, Morine Y, Fujii M, Ikegami T, Uehara H, Shimada M., Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase., Int J Clin Oncol, 13, 5, 452-457, 2008.10.
58. Ikegami T, Shimada M, Yoshizumi T, Imura S, Arakawa Y, Tokunaga T, Morine Y, Kanemura H., The timing of salvage liver transplantation after primary hepatectomy for hepatocellular carcinoma; a special reference to recurrence pattern and Milan criteria., Transplantation, 86, 5, 641-646, 2008.09.
59. Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, Harada N, Yamashita YI, Kawanaka H, Nishizak T, Maehara Y. , The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. , Transpl Int, 21, 9, 833-842, 2008.09.
60. Ikegami T, Soejima Y, Ohta R, Taketomi A, Yoshizumi T, Harada N, Kayashima H, Maehara Y. , Living donor liver transplantation for hepatitis B associated liver diseases: A 10-year experience in a single center, Hepatogastroenterology, 55, 85, 1445-1449, 2008.07.
61. Maeda T, Hashimoto K, Kihara K, Ikegami T, Ishida T, Aimitsu S, Fujiwara M., Surgically resected hepatocellular carcinoma in patients with non-alcholic steatohepatitis. , Hepatogastroenterology, 55, 85, 1404-1406, 2008.07.
62. Uemura T, Ikegami T, Sanchez EQ, Jennings LW, Narasimhan G, McKenna GJ, Randall HB, Chinnakotla S, Levy MF, Goldstein RM, Klintmalm GB. , Late acute rejection after liver transplantation impacts patient survival.
Clin Transplant, 2008.5;22(3):316-323.
, Clin Transplant, 22, 3, 316-323, 2008.05.
63. Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Maehara Y. , Living donor liver transplantation for fulminant hepatic failure from ABO-incompatible donors., Transplant Int, 21, 3, 284-285, 2008.03.
64. Ikegami T, Soejima Y, Taketomi A, Yoshizumi T, Harada N, Kayashima H, Itoh S, Yamashita Y, Maehara Y., Hilar anatomical variations in living donor liver transplantation using right lobe grafts., Dig Surg, 25, 2, 117-123, 2008.01.
65. Ikegami T, Taketomi A, Ohta R, Soejima Y, Yoshizumi T, Shimada M, Maehara Y., Donor age in living donor liver transplantation., Transplant Proc, 40, 1471-1475, 2008.01.
66. Ikegami T, Sanchez EQ, Uemura T, Narasimhan G, Masannat O, Chinnakotla S, McKenna GJ, Randall HB, Levy MF, Goldstein RM, Klintmalm GB. , Liver transplantation for cystic fibrosis in adults., Surg Today, 38, 1, 26-29, 2008.01.
67. Yoshizumi T, Taketomi A, Soejima Y, Uchiyama H, Ikegami T, Harada N, Kayashima H, Yamashita YI, Shimada M, Maehara Y. , Impact of donor age and recipient status on left-lobe graft for living donor adult liver transplantation., Transpl Int, 21, 1, 81-88, 2008.01.
68. Harada N, Soejima Y, Taketomi A, Yoshizumi T, Ikegami T, Yamashita Y, Itoh S, Kuroda Y, Maehara M., Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver. , Transplantation, 85, 69-74, 2008.01.
69. Mori H, Shinohara H, Arakawa Y, Kanemura H, Ikemoto T, Imura S, Morine Y, Ikegami T, Yoshizumi T, Shimada M., Beneficial effects of hyperbaric oxygen pretreatment on massive hepatectomy model in rats., Transplantation, 84, 12, 1656-1661, 2007.12.
70. Ikegami T, Soejima Y, Taketomi A, Yoshizumi T, Kayashima H, Uchiyama H, Shimada M, Maehara Y. , Explanted portal vein for middle hepatic vein tributaries in right lobe living donor liver transplantation. , Transplantation, 84, 7, 836-841, 2007.10.
71. Soejima Y, Ikegami T, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yamashita Y, Maehara Y. , Hepatitis B vaccination after living donor liver transplantation., Liver Int, 27, 7, 977-982, 2007.09.
72. Uemura T, Randall HB, Sanchez EQ, Ikegami T, Narasimhan G, McKenna GJ, Chinnakotla S, Levy MF, Goldstein RM, Klintmalm GB., Liver retransplantation for primary nonfunction: Analysis of a 20-year single-center experience. , Liver Transpl, 13, 2, 227-233, 2007.02.
73. Ueno T, Jones G, Martin A, Ikegami T, Sanchez EQ, Chinnakotla S, Randall HB, Levy MF, Goldstein RM, Klintmalm GB. , Clinical outcomes from hepatic artery stenting in liver transplantation., Liver Transpl, 12, 3, 422-427, 2006.03.
74. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, Levy MF, Chinnakotla S, Dawson S 3rd, Randall HB, Saracino G, Klintmalm GB., Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years.
, Transplant Proc, 37, 10, 4416-4623, 2005.12.
75. Ezaki T, Ikegami T, Maeda T, Yamada T, Ishida T, Hashizume M, Maehara Y. , Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma., Int J Clin Oncol, 10, 3, 171-176, 2005.06.
76. Ikegami T, Ezaki T, Ishida T, Aimitsu S, Fujihara M, Mori M. , Limited hepatic resection for hepatocellular carcinoma in the caudate lobe. , World J Surg, 28, 7, 697-701, 2004.07.
77. Ezaki T, Ikegami T, Ishida T, Aimitsu S, Mori M, Fujihara M. , Significance of thymidine phosphorylase in HCC with chronic liver disease for long-term postoperative recurrence., J Surg Oncol, 83, 3, 173-179, 2003.07.
78. Nishizaki T, Hiroshige S, Ikegami T, Uchiyama H, Hashimoto K, Soejima Y, Shimada M., Living-donor liver transplantation for fulminant hepatic failure in adult patients with a left-lobe graft., Surgery, 10.1067/msy.2002.119574, 131, 1, S182-S189, 2002.01.
79. kegami T, Nishizaki T, Ohta R, Kishikawa K, Yoshizumi T, Uchiyama H, Sugimachi K., Biliary reconstruction with dye injection leakage test and without stent use in living donor liver transplantation. , Hepatogastroenterology, 48, 42, 1582-1584, 2001.10.
80. Nishizaki T, Ikegami T, Hiroshige S,Hashimoto K, Uchiyama H, Yoshizumi Y, Kishikawa K, Nomoto K, Shimada M, Sugimachi K. , Small graft for living donor liver transplantation. , Ann Surg, 10.1097/00000658-200104000-00014, 233, 4, 575-580, 2001.04.
81. Yanaga K, Nishizaki T, Nomoto K, Ikegami T, Hashimoto K, Minagawa R, Ohta R, Hiroshige S, Sugimachi K. , Safety limit of small partial liver allografts for orthotopic transplantation., Transplant Proc, 32, 1-2, 1498-1499, 2001.02.
82. Ikegami T, Nishizaki T, Yanaga K, Shimada M, Kakizoe S, Nomoto K, Hiroshige S, Sugimachi K., Changes of caudate lobe, transplanted with extended left lobe liver graft from living donors., Surgery, 129, 1, 76-85, 2001.01.
83. Ikegami T, Nishizaki T, Yanaga K, Hiroshige S, Ohta R, Sugimachi K. , Experimental study of type 3 phosphodiesterase inhibitor on liver graft function. , Br J Surg, 88, 1, 59-64, 2001.01.
84. Ikegami T, Nishizaki, Yanaga K, Shimada M, Kishikawa K, Nomoto K, Uchiyama H, Sugimachi K., The impact of donor age on living donor liver transplantation., Transplantation, 10.1097/00007890-200012270-00007, 70, 12, 1703-1707, 2000.12.
85. Ikegami T, Nishizaki T, Uchiyama H, Hashimoto K, Yanaga K, Sugimachi K., Doubly armed short sutures are useful for microsurgical hepatic artery reconstruction in living related liver transplantation. , Hepatogastroenterology, 47, 34, 1103-1104, 2000.07.
86. Ikegami T, Nishizaki T, Yanaga K, Ohta R, Hiroshige S, Sugimachi K., A novel auxiliary partial orthotopic liver transplantation model in rats. , Eur Surg Res, 10.1159/000008774, 32, 5, 267-273, 2000.01.
87. Ikegami T, Nishizaki T, Uchiyama H, Hashimoto K, Yanaga K, Sugimachi K., Experimental study of the deletion variant of hepatocyte growth factor on hepatic ischemia-reperfusion injury. , Br J Surg, 87, 1, 59-64, 2000.01.
88. Yanaga K, Ikegami T, Hashimoto K, Nomoto K, Nishizaki T, Sugimachi K. , Overseas liver transplantation for Japanese patients., Transplant Proc, 10.1016/S0041-1345(99)00224-9, 31, 5, 1951-1951, 1999.08.
89. Nishizaki T, Okano S, Uchiyama H, Ikegami T, Hashimoto K, Minagawa R, Ohta R, Sugimachi K., Intraoperative hyaluronic acid clearance predicts postoperative graft function in living related liver transplantation. , Int Surg, 84, 3, 262-265, 1999.07.
90. Ikegami T, Nishizaki T, Uchiyama H, Kakizoe S, Yanaga K, Sugimachi K., Deletion variant of hepatocyte growth factor prolongs allograft survival after liver transplantation in rats., Surgery, 10.1067/msy.1999.98234, 125, 6, 602-607, 1999.06.